Compile Data Set for Download or QSAR
maximum 50k data
Found 24 Enz. Inhib. hit(s) with all data for entry = 6160
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112665(US8623863, 2-8)
Affinity DataKi:  3.30nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112672(US8623863, 3-5)
Affinity DataKi:  3.80nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112669(US8623863, 3-2)
Affinity DataKi:  4.20nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Rattus norvegicus (Rat))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112674(US8623863, 3-8)
Affinity DataKi:  5.10nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112664(US8623863, 1-8)
Affinity DataKi:  7.90nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Rattus norvegicus (Rat))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112665(US8623863, 2-8)
Affinity DataKi:  8.70nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112674(US8623863, 3-8)
Affinity DataKi:  8.70nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112667(US8623863, 2-10)
Affinity DataKi:  9.70nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112666(US8623863, 2-9)
Affinity DataKi:  10nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112670(US8623863, 3-3)
Affinity DataKi:  10nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112675(US8623863, 4-9)
Affinity DataKi:  11nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112671(US8623863, 3-4)
Affinity DataKi:  13nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112673(US8623863, 3-6)
Affinity DataKi:  14nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Rattus norvegicus (Rat))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112664(US8623863, 1-8)
Affinity DataKi:  15nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112668(US8623863, 2-11)
Affinity DataKi:  28nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Rattus norvegicus (Rat))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112669(US8623863, 3-2)
Affinity DataKi:  29nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Rattus norvegicus (Rat))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112675(US8623863, 4-9)
Affinity DataKi:  39nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Rattus norvegicus (Rat))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112670(US8623863, 3-3)
Affinity DataKi:  42nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Rattus norvegicus (Rat))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112666(US8623863, 2-9)
Affinity DataKi:  50nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Rattus norvegicus (Rat))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112672(US8623863, 3-5)
Affinity DataKi:  73nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Rattus norvegicus (Rat))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112671(US8623863, 3-4)
Affinity DataKi:  110nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Rattus norvegicus (Rat))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112667(US8623863, 2-10)
Affinity DataKi:  150nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Rattus norvegicus (Rat))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112668(US8623863, 2-11)
Affinity DataKi:  190nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Rattus norvegicus (Rat))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM112673(US8623863, 3-6)
Affinity DataKi:  310nMAssay Description:Compound potency can be assessed by a radioligand binding assay (described in Bergman et. al. Bioorg. Med. Chem. Lett. 2008, 18, 1425-1430) in which ...More data for this Ligand-Target Pair
In DepthDetails US Patent